medigraphic.com
Centro de Investigaciones Regionales Dr. Hideyo Noguchi, Universidad Autónoma de Yucatán

2007, Number 3

<< Back

Rev Biomed 2007; 18 (3)

Muscle waste in cancer cachexia, proteolytic mechanism

Moore-Carrasco R, Poblete-Bustamante M, González-Guerra O, Guajardo-Palavecino L, Palomo-González I

Language: Spanish
References: 60
Page: 182-191
PDF size: 310.64 Kb.


ABSTRACT

The cachexia associated to neoplasm is a syndrome characterized by a remarkable loss of weight, anorexia, loss of muscle mass and anemia. In fact, a high percentage of patients who die of advanced cancer show cachexia. The cachexia condition is associated with the presence and the growth of tumor that produces a condition of malnutrition as a consequence of anorexia. On the other hand, the metabolic disorders and the competence for nutrients between tumoral and normal cells induce an accelerated condition of wear out of patients. Though, it is certain that this accelerated wear out is caused by anorexia and the metabolic disorders that produce the hypermetabolism, all together explain to a great extent the events present in this syndrome however, the molecular disfunctios cannot be left aside. In this sense the proteolytic system is of great importance, in animal models with developed tumors as in patients with cancer, it is observed an increase in the expression and activity of the proteolyses system; both, lysosomal and non lysosomal, in particular the proteolytic system dependent of ATP and ubiquitin “proteasome”.


REFERENCES

  1. Tisdale M. Cachexia in cancer patients. Nat Rev Cancer 2002; 2(11):862-71.

  2. Studley HO. Percentage of weight loss: a basic indicator of surgical risk in patients with chronic peptic ulcer. J Am Med Assoc 1936; 106:458-61.

  3. Van Eys J. Effects of nutritional status in response to therapy. Cancer Res 1982; 42:S747-53.

  4. De Wys Wd, Begg C, Lavin PT, Band PR, Bennet JM, Bertino JR, et al. Prognostic effect of weight loss prior to chemotherapy in cancer patiens. Am J Med 1980; 69:491-97.

  5. Kolter DP. Cachexia. Amm Inter Med 2000; 133:622–634.

  6. Nixon DW, Heymsfield SB, Cohen AE, Kutner MH, Anslay J, Lawson DH. et al. Protein-calorie undernu-trition in hospitalized cancer patients. Am J Med 1980; 68:683-690.

  7. Argiles JM, Moore-Carrasco R, Busquets S, López- Soriano FJ. Catabolic mediators as targets for cancer cachexia. Drug Discov Today 2003 Sep 15; 8(18):838-44.

  8. Schein PS, Macdonald JS, Waters C, Haidak D. Nutritional complications of cancer and its treatment. Semin Oncol 1975; 2:337-47.

  9. Argilés JM and López-Soriano FJ. Catabolic proinflammatory cytokines. Curr Opin Clin Nutr Metab Care 1998; 1:245-251.

  10. Argilés JM and López-Soriano FJ. The enzymatic activities of branched-chain amino acid catabolism in tumour-bearing rats. Cancer Lett 1992; 61:239-42.

  11. Beck SA, Tisdale MJ. Production of lipolytic and proteolytic factors by a murine tumor-producing cachexia in the host. Cancer Res 1987; 47:5919-23.

  12. Samis JA and Elce JS. Immunogold electron-microscopic localization of calpain I in human erythrocytes. Tromb Haemost 1989; 61:250-53.

  13. Spalla M, Tsang W, Kuo TH, Giacomelli F, Wiener J. Purification and characterization of two distinct Ca2+-activated proteinases from hearts of hypertensive rats. Biochim Biophys Acta 1985; 830:258-66.

  14. Moyen C, Goudenege S, Poussard S, Sassi AH, Brustis JJ, Cottin P. Involvement of micro calpain (CAPN 1) in muscle cell differentiation. Int J Biochem Cell Bio 2004; 36(4):728-43.

  15. Busquets S, Alvarez B, Llovera M, Agell N, López- Soriano FJ, Argilés JM. Branched-chain amino acids inhibit proteolysis in rat skeletal muscle: mechanisms involved. J Cell Physiol 2000; 184:380-84.

  16. Costelli P, Reffo P, Penna F, Autelli R, Bonelli G, Baccino FM. Ca(2+)-dependent proteolysis in muscle wasting. Int J Biochem Cell Biol 2005; 37:2134-46.

  17. Schlesinger MJ. The ubiquitin system and the heat shock response. En: Schlensinger, Santoro, Garaci, Ed. Stress Proteins. Berlín Heidelberg: editorial Springer-Verlag, 1990; 81-88

  18. Vijay-Kurnar s, Bugg CE, Cook WJ. Structure of ubiquitin refined at 1.8 A resolution. J Mol Biol 1987; 194:531-44.

  19. Weber P, Brown S, Mueller L. 1H-NMR resonance assigments and secondary structure identification of human ubiquitin. Biochemistry 1987; 26:7282-90.

  20. Cary PD, King DS, Crane-Robinson C, Bradbury EM, Rabbini L, Goodwin G, et al. Structural studies on two high-mobility-group proteins from call thymus HMG-14 and HMG-20 (ubiquitin) and their interaction with DNA. Eur J Biochem 1980; 112:577-80.

  21. Haas AL and Bright PM. The immunochemical detection and quantitation of intracellular ubiquitin-protein conjugates. J Biol Chem. 1985; 260:12464-73.

  22. Carlson N and Rechsteiner M. Microinjection of ubiquitin: intracellular distribution and metabolism in HeLa cells maintained under normal physiological function. J Cell Biol 1987; 104:537-46.

  23. Rechsteiner M. Ubiquitin-mediated pathways for intracellular proteolysis. Annu Rev Cell Biol 1987; 3:1-30.

  24. Jentsch S. The ubiquitin-conjugation system. Annu Rev Genet 1992; 26:179-207.

  25. VarshaVsky A. The N-end rule. Cell 1992; 69:725-35.

  26. Trausch JS, Grenfell SJ. Handley-Gearhart PM, Ciechanover A, Schwart AL. Immunofluorescent localization of the ubiquitin-activating enzyme, E1, to the nucleus and cytoskeleton. Am J Physiol 1993; 264:C93-C102.

  27. Ciechanover A and Schwartz AL. How are substrates recognized by the ubiquitin-mediated proteolytic system? Trends Biochem Sci 1989; 14:483-8.

  28. Tysdale. Molecular pathways leading to cancer cachexia. Physiology 2005; 20:340-48.

  29. Goldberg AL and Rock KL. Proteolysis, proteasomes and antigen presentation. Nature 1992; 357:375-9.

  30. Rivett AJ. Proteasomes: multicatalytic proteinase complexes. Biochem J 1993; 291:1-10.

  31. Matsui S, Sandberg AA, Negoro S, Sean BK, Goldstein G. Isopeptidase: a novel eukaryotic enzyme that cleaves isopeptide bonds. Proc Natl Acad Sci USA 1982; 79:1535-9.

  32. Peters JM. Proteasomes: protein degradation machines of the cell. Trends Biochem Sci 1994; 19:377-82.

  33. Driscoll J and Goldberg AL. The proteasome (multicatalytic protease) is a component of the 1,500-kDa proteolytic complex wich degrades ubiquitin-conjugated proteins. J Biol Chem 1990; 265:4789-92.

  34. Goldkn OPF. I.L., Busch, H. Remarkable similarities of peptide fingerprints of histone 2A and nonhistone chromosomal protein A24. Biochem Biophys Res Commun 1975; 65:951-60.

  35. Yarden Y, Escobedo JA, Kuang WJ, Yang-Feng TL, Daniel TO, Tremble PM, et al. Structure of the receptor for platelet-derived growth factor helps define a family of closely related growth factor receptors. Nature 1986; 323:226-32.

  36. Wilkinson KD. Ubiquitin-dependent signaling: the role of ubiquitination in the response of cells to their environment. J Nutr 1999; 129:1933-6.

  37. Glotzer M, Murray AW and Kirschener MW. Cyclin is degraded by the ubiquitin pathway. Nature 1991; 349:132-8.

  38. Hasselgren PO, Fischer JE. Muscle cachexia: current concepts of intracellular mechanisms and molecular regulation. Ann Surg 2001; 233:9-17.

  39. Bachmair A, Finley D and Varsha Vsky A. In vivo half-life of a protein is a function of its amino-terminal residue. Science 1986; 234:179-86.

  40. Rogers S, Wells R and Rechsteiner M. Amino acid sequences common to rapidly degraded proteins: the PEST hypothesis. Science 1986; 234:364-8.

  41. Rechsteiner M. PEST sequences are signals for rapid intracellular proteolysis. Semin Cell Biol 1990; 1:433-40.

  42. Furuno K and Goldberg AL. The activation of protein degradation in muscle by Ca2+ or muscle injury does not involve a lysosomal mechanism. Biochem J 1986; 237:859-64.

  43. Han HQ, Furuno QF, Goldberg AL. The activation of the ATP-dependent proteolytic system in skeletal muscle during denervation atrophy and fasting. Federation Proc 1988; 2:A564.

  44. Llovera M, García-Martínez C, Agell N, Marzabal M, López-Soriano FJ and Argilés JM. Ubiquitin gene expression is increased in skeletal muscle of tumourbearing rats. FEBS Lett 1994; 338:311-8.

  45. Llovera M, García-Martínez C, Agell N, López-Soriano FJ and Argilés JM. Muscle wasting associated with cachexia is linked to an important activation of the ATP-dependent ubiquitin-mediated proteolysis. Int J Cancer 1995; 61:138-41.

  46. Dejong CH, Busquets S, Moses AG, Schrauwen P, Ross JA, Argiles JM, Fearon KC. Systemic inflammation correlates with increased expression of skeletal muscle ubiquitin but not uncoupling proteins in cancer cachexia. Oncol Rep 2005; 14:257-63.

  47. Bossola M, Muscaritoli M, Costelli P, Bellantone R, Pacelli F, Busquets S, et al. Increased muscle ubiquitin mRNA levels in gastric cancer patients. Am J Physiol Regul Integr Comp Physiol 2001; 280:R1518-1523.

  48. Llovera M, García-Martínez C, Costelli P, Agell N, Carbó N, López-Soriano FJ, et al. Muscle hypercatabolism during cancer cachexia is not reversed by the glucocorticoid receptor antagonist RU38486. Cancer Lett 1996; 99:7-14.

  49. Wing SS and Goldberg AL. Glucocorticoids activate the ATP-ubiquitin-dependent proteolytic system in skeletal muscle during fasting. Am J Physiol 1993; 264: E668-676.

  50. Costelli P, Llovera M, Carbó N, García-Martínez C, López-Soriano FJ, Argilés JM. Interleukin-1 receptor antagonist (IL-1ra) is unable to reverse cachexia in rats bearing an ascites hepatoma (Yoshida AH-130). Cancer Lett 1995; 95:33-8.

  51. Llovera M, Carbó N, García-Martínez C, Costelli P, Tessitore L, Baccino FM, et al. Anti-TNF treatment reverts increased muscle ubiquitin gene expression in tumour-bearing rats. Biochem Biophys Res Commun 1996; 221:653-5.

  52. Llovera M, García-Martínez C, López-Soriano J, Carbó N, Agell N, López-Soriano FJ, et al. Role of TNF receptor 1 in protein turnover during cancer cachexia using gene knockout mice. Mol Cell Endocrinol 1998; 142:183-9.

  53. Llovera M, García-Martínez C, López-Soriano J, Agell N, López-Soriano FJ, García I, et al. Protein turnover in skeletal muscle of tumour-bearing transgenic mice overexpressing the soluble TNF receptor-1. Cancer Lett 1998; 130:19-27.

  54. García-Martínez C, Llovera M, Agell N, López-Soriano FJ, Argilés JM. Ubiquitin gene expression in skeletal muscle is increased by tumour necrosis factor-alpha. Biochem Biophys Res Commun 1994; 201:682-6.

  55. Llovera M, García-Martínez C, Agell N, López-Soriano FJ and Argilés JM. TNF can directly induce the expression of ubiquitin-dependent proteolytic system in rat soleus muscles. Biochem Biophys Res Commun 1997; 230:238-41.

  56. Helliwell TR, Wilkinson A, Griffithst RD, Mcclelland P, Palmer Tea, Bone JM. Muscle fiber atrophy in critically ill patients is associated with the loss of myosin filaments and the presence of lysosomal enzymes and ubiquitin. Neuropathol Appl Neurobiol 1998; 24:507-17.

  57. Riley DA, Bain JLW, Ellis S, Haas AL. Quantitation and immunocytochemical localization of ubiquitin conjugates within rat red and white skeletal muscles. J Histochem Cytochem 1988; 36:621-32.

  58. Li JB and Goldberg AL. Effects of food deprivation on protein synthesis and degradation in rat skeletal muscles. Am J Physiol 1976; 231:441-4.

  59. Argilés JM, Almendro V, Busquets S, López-Soriano FJ. The pharmacological treatment of cachexia. Curr Drug Targets 2004; 5:265-77.

  60. Argilés JM, López-Soriano J, Busquets S, López-Soriano FJ. Journey from caquexia to obesity by TNF. FASEB J 1997; 11:743-51.




2020     |     www.medigraphic.com